for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Indoco Remedies Ltd

INRM.NS

Latest Trade

148.55INR

Change

-3.05(-2.01%)

Volume

10,902

Today's Range

147.25

 - 

154.40

52 Week Range

132.45

 - 

238.70

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
151.60
Open
153.90
Volume
10,902
3M AVG Volume
0.85
Today's High
154.40
Today's Low
147.25
52 Week High
238.70
52 Week Low
132.45
Shares Out (MIL)
92.15
Market Cap (MIL)
13,969.99
Forward P/E
29.61
Dividend (Yield %)
0.20

Latest Developments

More

Indoco Remedies' Clinical Research Organisation Gets No 483S From USFDA

Indoco Remedies Says UK-MHRA Reinstates Full GMP Status For Goa Plant

Indoco Remedies Says ICRA Cuts Long Term Rating To Icra A From Icra A+

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Indoco Remedies Ltd

Indoco Remedies Limited is an India-based company, which is engaged in the manufacture of pharmaceutical products. The Company primarily manufactures and markets Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The Company's geographical segments include India and Outside India. It offers products for various therapeutic categories, such as stomatologicals, respiratory, anti-infectives, gastrointestinal, pain/analgesics, gynecological, vitamins/minerals/nutrients, ophthal/otologicals and dermatology. Its domestic marketing divisions include INDOCO, SPADE, Warren NxGen, Warren Ace, Spera, Indoco Focus, Indoco CND, Warren Excel, Warren Vision, Eterna, Institution and Indoco IMPULSE. The Company's products include Sensodent-K, Homide, Carmicide, Renolen, Rexidin M, Febrex Plus, Zincoren, Otorex, Cloben G, Methycal, Tuspel, Scabex, Hemsyl, Karvol Plus, Durashape, Lignox, Sensoform Toothpaste, Kidodent Toothpaste, Rosuchek D, Otichek and Irimist.

Industry

Biotechnology & Drugs

Contact Info

166 Indoco House

Cst Road, Santacruz East

+91.22.26541851

http://www.indoco.com/

Executive Leadership

Suresh G. Kare

Executive Chairman of the Board

Aditi Kare Panandikar

Chief Executive Officer, Managing Director, Executive Director

Mandar Borkar

Chief Financial Officer

Mangesh Rajadhyaksha

President - API

Jayshankar Menon

Compliance Officer, Company Secretary

Key Stats

2.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

10.7K

2018

10.2K

2019

9.4K

2020(E)

11.4K
EPS (INR)

2017

8.360

2018

4.470

2019

-0.310

2020(E)

5.120
Price To Earnings (TTM)
130.85
Price To Sales (TTM)
1.39
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
16.93
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Indoco Remedies Gets European GMP Certification For Manufacturing Facility In Goa

* GOT EUROPEAN GMP CERTIFICATION FROM REGULATORY AUTHORITY OF HUNGARY FOR MANUFACTURING FACILITY OF NON-STERILE PRODUCTS IN GOA Source text: http://bit.ly/2sxPO9u Further company coverage:

BRIEF-India's Indoco Remedies Gets 8 Observations From U.S. FDA

* GETS 8 OBSERVATIONS FROM U.S. FDA AFTER INSPECTION OF CO'S SOLID DOSAGE PLANT IN GOA Source text - http://bit.ly/2HaiQPW Further company coverage:

BRIEF-India's Indoco Remedies Dec-Qtr Profit Rises

* DEC QUARTER PROFIT 226.6 MILLION RUPEES VERSUS PROFIT 175.9 MILLION RUPEES YEAR AGO

BRIEF-Indoco Remedies to start production of existing ophthalmic products from Goa plant II

* Says co to start production of existing ophthalmic products from Goa plant II for U.S. market Source text - http://bit.ly/2h8Hqol Further company coverage:

BRIEF-India's Indoco Remedies Sept-qtr profit down nearly 11 pct

* Sept quarter profit 197.6 million rupees versus profit of 221.3 million rupees last year

BRIEF-India's Indoco Remedies says Mandar Borkar re-designated as CFO

* Says Sundeep Bambolkar, joint MD and CFO ceases to be CFO of co

BRIEF-India's Indoco Remedies posts June-qtr loss

* June quarter loss 217.3 million rupees versus profit of 197.9 million rupees last year

BRIEF-India's Indoco Remedies March-qtr profit down about 14 pct

* Indoco Remedies Ltd consensus forecast for march quarter net profit was 225.5 million rupees

BRIEF-Indoco Remedies receives approval from UK-MHRA for facility in Goa

* Says received approval from regulatory body, UK-MHRA for its solid dosages manufacturing facility in Goa Source text - (http://bit.ly/2pC15Qn) Further company coverage:

BRIEF-Indoco Remedies gets form 483 from USFDA for inspection at Goa facility

* Says USFDA had inspected drug manufacturing facility at Verna, Goa, from August 31st 2016 to September 4th, 2016

BRIEF-Indoco Remedies gets members' nod to re-appoint Aditi Panandikar as MD

* Gets members' nod for re-appointment of Aditi Panandikar as MD

BRIEF-Indoco Remedies seeks members' nod reappointment of Aditi Panandikar as managing director

* Seeks members' nod reappointment of Aditi Panandikar as managing director

BRIEF-Indoco Remedies Dec-qtr profit down about 7 pct

* Dec quarter total income from operations 2.78 billion rupees

BRIEF-Indoco Remedies Sept-qtr profit rises

* Sept quarter total income from operations 2.81 billion rupees

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up